{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T05:28:31Z","timestamp":1786512511008,"version":"build-2736575974"},"reference-count":62,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Olaparib, a small-molecule poly(ADP-ribose) polymerase (PARP) inhibitor, selectively impairs single-strand DNA repair and improves outcomes in patients with\n                      <jats:italic>BRCA1<\/jats:italic>\n                      -mutant cancers by promoting the accumulation of unrepaired DNA damage in tumor cells. It is increasingly used in combination with chemotherapy to enhance therapeutic efficacy and overcome resistance; however, its impact on ovarian function in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      mutation carriers remains unknown. Here, we investigated whether BRCA1 deficiency alters ovarian sensitivity to combined cyclophosphamide and olaparib exposure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Adult wild-type (WT;\n                      <jats:italic>Brca1<\/jats:italic>\n                      <jats:sup>fl\/fl<\/jats:sup>\n                      <jats:italic>Gdf9<\/jats:italic>\n                      <jats:sup>+\/+<\/jats:sup>\n                      ) and oocyte-specific\n                      <jats:italic>Brca1<\/jats:italic>\n                      conditional knockout (cKO;\n                      <jats:italic>Brca1<\/jats:italic>\n                      <jats:sup>fl\/fl<\/jats:sup>\n                      <jats:italic>Gdf9<\/jats:italic>\n                      <jats:sup>cre\/+<\/jats:sup>\n                      ) mice were treated with cyclophosphamide (75 mg\/kg, single intraperitoneal injection) or vehicle, followed by daily olaparib (50 mg\/kg, subcutaneous) or vehicle for 28 days.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ovarian reserve, endocrine function, estrous cyclicity, and IVF outcomes were assessed. Combination treatment did not affect serum AMH levels, estrous cyclicity, or IVF outcomes in either genotype, indicating no evidence of short-term impairment of reproductive function. Importantly though,\n                      <jats:italic>Brca1<\/jats:italic>\n                      cKO mice exposed to combination treatment exhibited long-term effects, evident from a significant depletion of primordial follicles compared with genotype-matched vehicle controls, whereas ovarian reserve remained preserved in WT animals receiving the same treatment regimen.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>\n                      These findings demonstrate that BRCA1 deficiency may confer selective susceptibility of the ovarian reserve to combination chemotherapy and PARP inhibitor exposure without immediate impairment of endocrine or reproductive function. This study provides the first evidence that\n                      <jats:italic>BRCA1<\/jats:italic>\n                      mutation carriers may be uniquely vulnerable to accelerated primordial follicle loss following chemotherapy PARP inhibitor combination therapy, with important implications for fertility preservation and long-term reproductive health in young women undergoing cancer treatment.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1885969","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:46:05Z","timestamp":1786509965000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Combination olaparib and cyclophosphamide cancer therapy exacerbates ovarian reserve depletion in mice with conditional loss of Brca1 in oocytes"],"prefix":"10.3389","volume":"17","author":[{"given":"Yujie","family":"Cao","sequence":"first","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaahida Abdul","family":"Jalil","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Mu","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica M","family":"Stringer","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadeen","family":"Zerafa","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Winship","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla J.","family":"Hutt","sequence":"additional","affiliation":[{"name":"Women\u2019s Health and Ovarian Biology Laboratory, Biomedicine Discovery Institute, Department of Anatomy and Developmental Biology, Development and Stem Cells Program, Monash University","place":["Clayton, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1210\/er.21.2.200","article-title":"Initial and cyclic recruitment of ovarian follicles","volume":"21","author":"McGee","year":"2000","journal-title":"Endocr Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/den285","article-title":"Ovarian failure following cancer treatment: current management and quality of life","volume":"23","author":"Absolom","year":"2009","journal-title":"Hum Reprod"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/dey216","article-title":"The impact of cancer on subsequent chance of pregnancy: a population-based analysis","volume":"33","author":"Anderson","year":"2018","journal-title":"Hum Reprod"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/01.ogx.0001169640.95001.fc","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpobgyn.2011.11.008","article-title":"Chemotherapy and fertility","volume":"26","author":"Blumenfeld","year":"2012","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.14511","article-title":"Clinicians' perspectives on barriers to discussing infertility and fertility preservation with young women with cancer","volume":"2","author":"Covelli","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.5247.283","article-title":"Cyclophosphamide in advanced breast cancer","volume":"2","author":"Stoll","year":"1961","journal-title":"Br Med J"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1961.03620090128016","article-title":"Cyclophosphamide therapy. Its use in leukemia, lymphoma and solid tumors","volume":"108","author":"Wall","year":"1961","journal-title":"Arch Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu146","article-title":"Ovarian xenobiotic biotransformation enzymes are altered during phosphoramide mustard-induced ovotoxicity","volume":"141","author":"Madden","year":"2014","journal-title":"Toxicol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.146","article-title":"Cyclophosphamide and cancer: golden anniversary","volume":"6","author":"Emadi","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ando.2023.03.013","article-title":"Chemotherapy and female fertility","volume":"84","author":"Sellami","year":"2023","journal-title":"Annales d'Endocrinologie"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: A Cancer J For Clin"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"Jama"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016600","article-title":"Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins","volume":"7","author":"Prakash","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph19138113","article-title":"Epithelial ovarian cancer: Providing evidence of predisposition genes","volume":"19","author":"Shah","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25010204","article-title":"BRCA mutations and fertility preservation","volume":"25","author":"Dias Nunes","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx639","article-title":"Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients","volume":"29","author":"Lambertini","year":"2018","journal-title":"Ann Oncol Off J Eur Soc For Med Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.20.02880","article-title":"Association of germline BRCA pathogenic variants with diminished ovarian reserve: a meta-analysis of individual patient-level data","volume":"39","author":"Turan","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105262","article-title":"Conditional loss of Brca1 in oocytes causes reduced litter size, ovarian reserve depletion and impaired oocyte in vitro maturation with advanced reproductive age in mice","volume":"106","author":"Winship","year":"2024","journal-title":"EBioMedicine"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/nrm.2017.53","article-title":"The multifaceted roles of PARP1 in DNA repair and chromatin remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12609-025-00582-5","article-title":"Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors","volume":"17","author":"Ray","year":"2025","journal-title":"Curr Breast Cancer Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.32604\/or.2023.028310","article-title":"Targeting DNA repair for cancer treatment: lessons from PARP inhibitor trials","volume":"31","author":"Nambiar","year":"2023","journal-title":"Oncol Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2008.16.0812","article-title":"A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair","volume":"26","author":"Ashworth","year":"2008","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-4953","article-title":"Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin","volume":"14","author":"Evers","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.2728","article-title":"Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation","volume":"33","author":"Kaufman","year":"2015","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604510","article-title":"Resistance to chemotherapy: new treatments and novel insights into an old problem","volume":"99","author":"Raguz","year":"2008","journal-title":"Br J Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.12688\/f1000research.6760.1","article-title":"Chemotherapy for late-stage cancer patients: meta-analysis of complete response rates","volume":"4","author":"Ashdown","year":"2015","journal-title":"F1000Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"73","DOI":"10.22259\/2638-4981.0201002","article-title":"PARP inhibitor combination therapy","volume":"108","author":"Dr\u00e9an","year":"2016","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1038\/s41467-025-56914-7","article-title":"Olaparib combined to metronomic cyclophosphamide and metformin in women with recurrent advanced\/metastatic endometrial cancer: the ENDOLA phase I\/II trial","volume":"16","author":"Piffoux","year":"2025","journal-title":"Nat Commun"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0192623315570339","article-title":"Vaginal cytology of the laboratory rat and mouse: review and criteria for the staging of the estrous cycle using stained vaginal smears","volume":"43","author":"Cora","year":"2015","journal-title":"Toxicol Pathol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13048-020-00724-6","article-title":"Comparison of methods for quantifying primordial follicles in the mouse ovary","volume":"13","author":"Sarma","year":"2020","journal-title":"J Ovarian Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3791\/61782-v","article-title":"Accurate follicle enumeration in adult mouse ovaries","author":"Winship","year":"2020","journal-title":"J Vis Exp"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11237209","article-title":"Clinical utilities of anti-M\u00fcllerian hormone","volume":"11","author":"Russell","year":"2022","journal-title":"J Clin Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bpobgyn.2021.09.011","article-title":"Premature ovarian insufficiency","volume":"81","author":"McGlacken-Byrne","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/s41572-024-00547-5","article-title":"Premature ovarian insufficiency","volume":"10","author":"Touraine","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098174","article-title":"Analysis of late-onset ovarian insufficiency after ovarian surgery: retrospective study with 75 patients of post-surgical ovarian insufficiency","volume":"9","author":"Takae","year":"2014","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ijrobp.2023.08.013","article-title":"Effects of radiation therapy on the female reproductive tract in childhood cancer survivors: a PENTEC comprehensive review","volume":"119","author":"Hill-Kayser","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215342","article-title":"The impact of chemotherapy on the ovaries: molecular aspects and the prevention of ovarian damage","volume":"20","author":"Sonigo","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1093\/humupd\/dmz027","article-title":"Ovarian damage from chemotherapy and current approaches to its protection","volume":"25","author":"Spears","year":"2019","journal-title":"Hum Reprod Update"},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.coemr.2020.12.004","article-title":"Evaluating the impacts of emerging cancer therapies on ovarian function","volume":"18","author":"Alesi","year":"2021","journal-title":"Curr Opin Endocr Metab Res"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3390\/life13051195","article-title":"The late effects of cancer treatment on female fertility and the current status of fertility preservation\u2014a narrative review","volume":"13","author":"Rodriguez-Wallberg","year":"2023","journal-title":"Life"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.18370\/2309-4117.2017.37.41-48","article-title":"ESHRE guideline: management of women with premature ovarian insufficiency","volume":"31","author":"Webber","year":"2016","journal-title":"Hum Reprod"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105730","article-title":"The cycle of stress: a systematic review of the impact of chronic psychological stress models on the rodent estrous cycle","volume":"162","author":"Poitras","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B44","article-title":"Ovarian toxicity of cyclophosphamide alone and in combination with ovarian irradiation in the rat","volume":"47","author":"Jarrell","year":"1987","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7827-8-51","article-title":"Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide","volume":"8","author":"Lemos","year":"2010","journal-title":"Reprod Biol Endocrinol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"31042","DOI":"10.1038\/s41598-024-82264-3","article-title":"Comparison of large single and small multiple doses of cyclophosphamide exposure in mice during early prepubertal age on fertility outcome","volume":"14","author":"Salian","year":"2024","journal-title":"Sci Rep"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/jog.16004","article-title":"Role of DNA damage response in cyclophosphamide-induced premature ovarian failure in mice","volume":"50","author":"Song","year":"2024","journal-title":"J Obstet Gynaecol Res"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2009.05.550","article-title":"Persistence of histone H2AX phosphorylation after meiotic chromosome synapsis and abnormal centromere cohesion in poly (ADP-ribose) polymerase (Parp-1) null oocytes","volume":"331","author":"Yang","year":"2009","journal-title":"Dev Biol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"17058","DOI":"10.1038\/s41598-020-74087-9","article-title":"Poly (ADP-ribose) polymerase inhibitor exposure reduces ovarian reserve followed by dysfunction in granulosa cells","volume":"10","author":"Nakamura","year":"2020","journal-title":"Sci Rep"},{"key":"B50","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/s41419-019-1961-y","article-title":"Kinase-independent inhibition of cyclophosphamide-induced pathways protects the ovarian reserve and prolongs fertility","volume":"10","author":"Bellusci","year":"2019","journal-title":"Cell Death Dis"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/molehr\/gaz020","article-title":"Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes","volume":"25","author":"Nguyen","year":"2019","journal-title":"Mol Hum Reprod"},{"key":"B52","doi-asserted-by":"publisher","first-page":"185ra62","DOI":"10.1126\/scitranslmed.3005402","article-title":"Cyclophosphamide triggers follicle activation and \"burnout\"; AS101 prevents follicle loss and preserves fertility","volume":"5","author":"Kalich-Philosoph","year":"2013","journal-title":"Sci Transl Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s13048-017-0350-3","article-title":"Rapamycin prevents cyclophosphamide-induced over-activation of primordial follicle pool through PI3K\/Akt\/mTOR signaling pathway in vivo","volume":"10","author":"Zhou","year":"2017","journal-title":"J Ovarian Res"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201801089r","article-title":"AMH prevents primordial ovarian follicle loss and fertility alteration in cyclophosphamide-treated mice","volume":"33","author":"Sonigo","year":"2019","journal-title":"FASEB J"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.275.20.15504","article-title":"Characterization of sPARP-1. An alternative product of PARP-1 gene with poly(ADP-ribose) polymerase activity independent of DNA strand breaks","volume":"275","author":"Sallmann","year":"2000","journal-title":"J Biol Chem"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.11.002","article-title":"NAD+-dependent modulation of chromatin structure and transcription by nucleosome binding properties of PARP-1","volume":"119","author":"Kim","year":"2004","journal-title":"Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nrg887","article-title":"Chromatin modification and epigenetic reprogramming in mammalian development","volume":"3","author":"Li","year":"2002","journal-title":"Nat Rev Genet"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature03368","article-title":"Chromatin remodelling and epigenetic features of germ cells","volume":"434","author":"Kimmins","year":"2005","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1095\/biolreprod.109.080697","article-title":"Oocyte numbers in the mouse increase after treatment with 5-aminoisoquinolinone: a potent inhibitor of poly(ADP-ribosyl)ation1","volume":"82","author":"Qian","year":"2010","journal-title":"Biol Reprod"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/1357-4310(96)10023-x","article-title":"Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis","volume":"53","author":"Kaufmann","year":"1993","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa128","article-title":"The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation","volume":"35","author":"Winship","year":"2020","journal-title":"Hum Reprod"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16412","article-title":"Susceptibility of Brca1((L63X\/+)) rat to ovarian reserve dissipation by chemotherapeutic agents to breast cancer","volume":"116","author":"Kaseki","year":"2025","journal-title":"Cancer Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1885969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T04:46:10Z","timestamp":1786509970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1885969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":62,"alternative-id":["10.3389\/fendo.2026.1885969"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1885969","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1885969"}}